🇺🇸 FDA
Patent

US 11878074

Methods of use of emulsion formulations of an NK-1 receptor antagonist

granted A61KA61K31/43A61K31/435

Quick answer

US patent 11878074 (Methods of use of emulsion formulations of an NK-1 receptor antagonist) held by Heron Therapeutics, Inc. expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Heron Therapeutics, Inc.
Grant date
Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/43, A61K31/435, A61K31/496, A61K31/5377